Breach of tolerance: Primary biliary cirrhosis

Seminars in Liver Disease

Volumn 34, Issue 3, 2014, Pages 297-317

  Wang, Lifeng ^a   Wang, Fu Sheng ^a   Chang, Christopher ^b   Gershwin, M Eric ^c  

^a BEIJING 302 HOSPITAL   (China)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antimitochondrial antibodies; apoptosis; autoreactive T cells; liver tolerance effect; pyruvate dehydrogenase complex

Indexed keywords

2 OXOACID DEHYDROGENASE; 2 OXOISOVALERATE DEHYDROGENASE (LIPOAMIDE); AUTOANTIBODY; AUTOANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR5; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; MICRORNA; MITOCHONDRION ANTIBODY; RITUXIMAB; SMALL INTERFERING RNA; THIOCTIC ACID; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; URSODEOXYCHOLIC ACID; XENOBIOTIC AGENT;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BILIARY EPITHELIAL CELL; BREACH OF TOLERANCE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CROSS REACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; EPITHELIUM CELL; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEPATOBILIARY PARAMETERS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LIVER CELL; LIVER TOLERANCE EFFECT; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; MOLECULAR MIMICRY; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY BILIARY CIRRHOSIS; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; X CHROMOSOME INACTIVATION; ANIMAL; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS, BILIARY; LIVER MITOCHONDRION; PATHOLOGY; RISK FACTOR;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNITY; BILE DUCTS, INTRAHEPATIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA, LIVER; MOLECULAR MIMICRY; RISK FACTORS; XENOBIOTICS;

EID: 84905011139     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1383729     Document Type: Article

References (255)

1. Kaplan M. M., Gershwin M. E. Primary biliary cirrhosis. N Engl J Med: 2005; 353 12 1261 1273
2. Perricone C., Colafrancesco S., Mazor R. D., Soriano A., Agmon-Levin N., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun: 2013; 47 1 16
3. Selmi C., Leung P. S., Sherr D. H., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun: 2012; 39 4 272 284
4. Hirschfield G. M., Gershwin M. E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol: 2013; 8 303 330
5. Wildner G., Kaufmann U. What causes relapses of autoimmune diseases? The etiological role of autoreactive T cells. Autoimmun Rev: 2013; 12 11 1070 1075
6. Mackay I. R. Autoimmunity since the 1957 clonal selection theory: a little acorn to a large oak. Immunol Cell Biol: 2008; 86 1 67 71
7. Cohn M., Mitchison N. A., Paul W. E., Silverstein A. M., Talmage D. W., Weigert M. Reflections on the clonal-selection theory. Nat Rev Immunol: 2007; 7 10 823 830
8. Billingham R. E., Brent L., Medawar P. B. Actively acquired tolerance of foreign cells. Nature: 1953; 172 4379 603 606
9. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. J Autoimmun: 2013; 45 97 103
10. Kappler J. W., Roehm N., Marrack P. T cell tolerance by clonal elimination in the thymus. Cell: 1987; 49 2 273 280
11. Kisielow P., Blüthmann H., Staerz U. D., Steinmetz M., von Boehmer H. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature: 1988; 333 6175 742 746
12. Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol: 2003; 3 5 383 391
13. Starr T. K., Jameson S. C., Hogquist K. A. Positive and negative selection of T cells. Annu Rev Immunol: 2003; 21 139 176
14. Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology: 2004; 111 2 138 146
15. Van Parijs L., Abbas A. K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science: 1998; 280 5361 243 248
16. Walker L. S., Abbas A. K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol: 2002; 2 1 11 19
17. Halverson R., Torres R. M., Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol: 2004; 5 6 645 650
18. Tiegs S. L., Russell D. M., Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med: 1993; 177 4 1009 1020
19. Eisenberg R. A. Secondary receptor editing in the generation of autoimmunity. Autoimmun Rev: 2012; 11 11 787 789
20. Goodnow C. C., Adelstein S., Basten A. The need for central and peripheral tolerance in the B cell repertoire. Science: 1990; 248 4961 1373 1379
21. Guerder S., Picarella D. E., Linsley P. S., Flavell R. A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A: 1994; 91 11 5138 5142
22. Weigle W. O. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv Immunol: 1980; 30 159 273
23. Pan P. Y., Ozao J., Zhou Z., Chen S. H. Advancements in immune tolerance. Adv Drug Deliv Rev: 2008; 60 2 91 105
24. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol: 2004; 22 531 562
25. Shevach E. M. Regulatory T cells in autoimmmunity*. Annu Rev Immunol: 2000; 18 423 449
26. Askenasy N. Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity. Autoimmun Rev: 2013; 12 10 972 975
27. Xiao J., Liu C., Li G., et al. PDCD5 negatively regulates autoimmunity by upregulating FOXP3(+) regulatory T cells and suppressing Th17 and Th1 responses. J Autoimmun: 2013; 47 34 44
28. Bogdanos D. P., Gao B., Gershwin M. E. Liver immunology. Compr Physiol: 2013; 3 2 567 598
29. Selmi C., Mackay I. R., Gershwin M. E. The immunological milieu of the liver. Semin Liver Dis: 2007; 27 2 129 139
30. Invernizzi P. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. J Autoimmun: 2013; 46 1 6
31. Tiegs G., Lohse A. W. Immune tolerance: what is unique about the liver. J Autoimmun: 2010; 34 1 1 6
32. Gianchecchi E., Delfino D. V., Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev: 2013; 12 11 1091 1100
33. Avrameas S., Selmi C. Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun: 2013; 41 46 49
34. Bailey M., Christoforidou Z., Lewis M. Evolution of immune systems: specificity and autoreactivity. Autoimmun Rev: 2013; 12 6 643 647
35. Gershwin M. E., Mackay I. R., Sturgess A., Coppel R. L. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol: 1987; 138 10 3525 3531
36. Selmi C., Mackay I. R., Gershwin M. E. The autoimmunity of primary biliary cirrhosis and the clonal selection theory. Immunol Cell Biol: 2011; 89 1 70 80
37. Duarte-Rey C., Bogdanos D., Yang C. Y., et al. Primary biliary cirrhosis and the nuclear pore complex. Autoimmun Rev: 2012; 11 12 898 902
38. Wakabayashi K., Lian Z. X., Moritoki Y., et al. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology: 2006; 44 5 1240 1249
39. Oertelt S., Lian Z. X., Cheng C. M., et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol: 2006; 177 3 1655 1660
40. Irie J., Wu Y., Wicker L. S., et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med: 2006; 203 5 1209 1219
41. Rose N. R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today: 1993; 14 9 426 430
42. Anaya J. M. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev: 2012; 11 11 781 784
43. Reed L. J., Hackert M. L. Structure-function relationships in dihydrolipoamide acyltransferases. J Biol Chem: 1990; 265 16 8971 8974
44. Meda F., Zuin M., Invernizzi P., Vergani D., Selmi C. Serum autoantibodies: a road map for the clinical hepatologist. Autoimmunity: 2008; 41 1 27 34
45. Gershwin M. E., Ansari A. A., Mackay I. R., et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev: 2000; 174 210 225
46. Bogdanos D. P., Smyk D. S., Invernizzi P., et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev: 2013; 12 7 726 740
47. Long S. A., Quan C., Van de Water J., et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol: 2001; 167 5 2956 2963
48. Long S. A., Van de Water J., Gershwin M. E. Antimitochondrial antibodies in primary biliary cirrhosis: the role of xenobiotics. Autoimmun Rev: 2002; 1 1-2 37 42
49. Ehser J., Holdener M., Christen S., et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun: 2013; 42 39 49
50. Fujiwara K., Yokosuka O. Frequent detection of immunoglobulin M anti-herpes simplex viral antibody in patients with primary biliary cirrhosis. Hepatology: 2012; 56 1 395
51. Xu L., Shen Z., Guo L., et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A: 2003; 100 14 8454 8459
52. Selmi C., Ross S. R., Ansari A. A., et al. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology: 2004; 127 2 493 501
53. Morshed S. A., Nishioka M., Saito I., Komiyama K., Moro I. Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients. Gastroenterol Jpn: 1992; 27 6 751 758
54. Uzoegwu P. N., Baum H., Williamson J. The occurrence and localization in trypanosomes and other endo-parasites of an antigen cross-reacting with mitochondrial antibodies of primary biliary cirrhosis. Comp Biochem Physiol B: 1987; 88 4 1181 1189
55. Sakly W., Jeddi M., Ghedira I. Anti- Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci: 2008; 53 7 1983 1987
56. Selmi C., De Santis M., Cavaciocchi F., Gershwin M. E. Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers: 2010; 29 6 287 299
57. Varyani F. K., West J., Card T. R. An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol: 2011; 11 95
58. Mattner J., Savage P. B., Leung P., et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe: 2008; 3 5 304 315
59. Kita H., Matsumura S., He X. S., et al. Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. Hepatology: 2002; 36 4 Pt 1 918 926
60. Ide T., Sata M., Suzuki H., et al. An experimental animal model of primary biliary cirrhosis induced by lipopolysaccharide and pyruvate dehydrogenase. Kurume Med J: 1996; 43 3 185 188
61. Haruta I., Hashimoto E., Shibata N., Kato Y., Kobayashi M., Shiratori K. Lipoteichoic acid may affect the pathogenesis of PBC-like bile duct damage and might be involved in systemic multifocal epithelial inflammations in chronic colitis-harboring TCRalpha-/-xAIM-/- mice. Autoimmunity: 2007; 40 5 372 379
62. Tarner I. H., Fathman C. G. Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease? Nat Clin Pract Rheumatol: 2006; 2 9 491 499
63. Jones D. E., Palmer J. M., Burt A. D., Walker C., Robe A. J., Kirby J. A. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. Hepatology: 2002; 36 3 679 686
64. Agmon-Levin N., Katz B. S., Shoenfeld Y. Infection and primary biliary cirrhosis. Isr Med Assoc J: 2009; 11 2 112 115
65. Dubel L., Tanaka A., Leung P. S., et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology: 1999; 29 4 1013 1018
66. Selmi C., Gershwin M. E. The retroviral myth of primary biliary cirrhosis: is this (finally) the end of the story? J Hepatol: 2009; 51 2 412 413, author reply 414-415
67. Leung P. S., Wang J., Naiyanetr P., et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun: 2013; 41 79 86
68. Leung P. S., Quan C., Park O., et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol: 2003; 170 10 5326 5332
69. Leung P. S., Rossaro L., Davis P. A., et al Acute Liver Failure Study Group Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology: 2007; 46 5 1436 1442
70. Naiyanetr P., Butler J. D., Meng L., et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J Autoimmun: 2011; 37 3 209 216
71. Rieger R., Leung P. S., Jeddeloh M. R., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun: 2006; 27 1 7 16
72. Leung P. S., Park O., Tsuneyama K., et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol: 2007; 179 4 2651 2657
73. Wakabayashi K., Yoshida K., Leung P. S., et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol: 2009; 155 3 577 586
74. Wakabayashi K., Lian Z. X., Leung P. S., et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology: 2008; 48 2 531 540
75. Gershwin M. E., Selmi C., Worman H. J., et al. USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology: 2005; 42 5 1194 1202
76. Prince M. I., Ducker S. J., James O. F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut: 2010; 59 4 508 512
77. Lleo A., Selmi C., Invernizzi P., Podda M., Gershwin M. E. The consequences of apoptosis in autoimmunity. J Autoimmun: 2008; 31 3 257 262
78. Elliott M. R., Ravichandran K. S. Clearance of apoptotic cells: implications in health and disease. J Cell Biol: 2010; 189 7 1059 1070
79. Clancy R. M., Neufing P. J., Zheng P., et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest: 2006; 116 9 2413 2422
80. Allina J., Hu B., Sullivan D. M., et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun: 2006; 27 4 232 241
81. Lleo A., Invernizzi P., Selmi C., et al. Autophagy: highlighting a novel player in the autoimmunity scenario. J Autoimmun: 2007; 29 2-3 61 68
82. Lleo A., Invernizzi P., Mackay I. R., Prince H., Zhong R. Q., Gershwin M. E. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol: 2008; 14 21 3328 3337
83. Gianchecchi E., Delfino D. V., Fierabracci A. Recent insights on the putative role of autophagy in autoimmune diseases. Autoimmun Rev: 2014; 13 3 231 241
84. Padgett K. A., Selmi C., Kenny T. P., et al. Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J Autoimmun: 2005; 24 3 209 219
85. Lleo A., Bowlus C. L., Yang G. X., et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology: 2010; 52 3 987 998
86. Odin J. A., Huebert R. C., Casciola-Rosen L., LaRusso N. F., Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest: 2001; 108 2 223 232
87. Sasaki M., Ikeda H., Nakanuma Y. Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/Cip1 in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. J Autoimmun: 2008; 31 1 73 78
88. Lleo A., Selmi C., Invernizzi P., et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology: 2009; 49 3 871 879
89. Allina J., Stanca C. M., Garber J., et al. Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun: 2008; 30 4 238 245
90. Parikh-Patel A., Gold E., Mackay I. R., Gershwin M. E. The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Clin Immunol: 1999; 91 2 206 218
91. Selmi C., Mayo M. J., Bach N., et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology: 2004; 127 2 485 492
92. Svyryd Y., Hernández-Molina G., Vargas F., Sánchez-Guerrero J., Segovia D. A., Mutchinick O. M. X chromosome monosomy in primary and overlapping autoimmune diseases. Autoimmun Rev: 2012; 11 5 301 304
93. Kelley J., Trowsdale J. Features of MHC and NK gene clusters. Transpl Immunol: 2005; 14 3-4 129 134
94. Invernizzi P., Battezzati P. M., Crosignani A., et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol: 2003; 38 4 401 406
95. Donaldson P. T., Baragiotta A., Heneghan M. A., et al. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology: 2006; 44 3 667 674
96. Donaldson P. T. TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal. J Hepatol: 1999; 31 2 366 368
97. Juran B. D., Hirschfield G. M., Invernizzi P., et al. Italian PBC Genetics Study Group. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet: 2012; 21 23 5209 5221
98. Liu J. Z., Almarri M. A., Gaffney D. J., et al. UK Primary Biliary Cirrhosis (PBC) Consortium; Wellcome Trust Case Control Consortium 3. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet: 2012; 44 10 1137 1141
99. Umemura T., Joshita S., Ichijo T., et al. Shinshu PBC Study Group. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology: 2012; 55 2 506 511
100. Invernizzi P., Ransom M., Raychaudhuri S., et al. Italian PBC Genetics Study Group. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes Immun: 2012; 13 6 461 468
101. Zhao D. T., Liao H. Y., Zhang X., et al. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. Liver Int: 2014; 34 2 220 226
102. Mells G. F., Kaser A., Karlsen T. H. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun: 2013; 46 41 54
103. Liu X., Invernizzi P., Lu Y., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet: 2010; 42 8 658 660
104. Hirschfield G. M., Liu X., Xu C., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med: 2009; 360 24 2544 2555
105. Hirschfield G. M., Siminovitch K. A. Toward the molecular dissection of primary biliary cirrhosis. Hepatology: 2009; 50 5 1347 1350
106. Watford W. T., Hissong B. D., Bream J. H., Kanno Y., Muul L., O'Shea J. J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev: 2004; 202 139 156
107. Tamiya T., Kashiwagi I., Takahashi R., Yasukawa H., Yoshimura A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol: 2011; 31 5 980 985
108. Hu G., Barnes B. J. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J Biol Chem: 2009; 284 5 2767 2777
109. Krausgruber T., Blazek K., Smallie T., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol: 2011; 12 3 231 238
110. Zhang X., Ing S., Fraser A., et al. Follicular helper T cells: new insights into mechanisms of autoimmune diseases. Ochsner J: 2013; 13 1 131 139
111. Wang J. H., Avitahl N., Cariappa A., et al. Aiolos regulates B cell activation and maturation to effector state. Immunity: 1998; 9 4 543 553
112. Hirschfield G. M., Xie G., Lu E., et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun: 2012; 13 4 328 335
113. Nakamura M., Nishida N., Kawashima M., et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet: 2012; 91 4 721 728
114. Li M., Zheng H., Li T., Gao P., Zhang X. L., Liu D. W. Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review. J Gastroenterol Hepatol: 2012; 27 7 1159 1166
115. Donaldson P., Agarwal K., Craggs A., Craig W., James O., Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut: 2001; 48 3 397 402
116. Vogel A., Strassburg C. P., Manns M. P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology: 2002; 35 1 126 131
117. Gianchecchi E., Palombi M., Fierabracci A. The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. Autoimmun Rev: 2013; 12 7 717 725
118. Zheng J., Petersen F., Yu X. The role of PTPN22 in autoimmunity: learning from mice. Autoimmun Rev: 2014; 13 3 266 271
119. Zhou V. W., Goren A., Bernstein B. E. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet: 2011; 12 1 7 18
120. Bogdanos D. P., Smyk D. S., Rigopoulou E. I., et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun: 2012; 38 2-3 J156 J169
121. Costenbader K. H., Gay S., Alarcón-Riquelme M. E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev: 2012; 11 8 604 609
122. Katoh H., Zheng P., Liu Y. FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun: 2013; 41 72 78
123. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun: 2013; 41 1 5
124. Luo Y., Wang Y., Wang Q., Xiao R., Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun: 2013; 41 161 167
125. Wang Q., Selmi C., Zhou X., et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun: 2013; 41 140 145
126. Higuchi M., Horiuchi T., Kojima T., et al. Analysis of CD40 ligand gene mutations in patients with primary biliary cirrhosis. Scand J Clin Lab Invest: 1998; 58 5 429 432
127. Lleo A., Liao J., Invernizzi P., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology: 2012; 55 1 153 160
128. Bianchi I., Lleo A., Gershwin M. E., Invernizzi P. The X chromosome and immune associated genes. J Autoimmun: 2012; 38 2-3 J187 J192
129. Borchers A. T., Gershwin M. E. Sociological differences between women and men: implications for autoimmunity. Autoimmun Rev: 2012; 11 6-7 A413 A421
130. Lee T. P., Chiang B. L. Sex differences in spontaneous versus induced animal models of autoimmunity. Autoimmun Rev: 2012; 11 6-7 A422 A429
131. Moroni L., Bianchi I., Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev: 2012; 11 6-7 A386 A392
132. Nussinovitch U., Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev: 2012; 11 6-7 A377 A385
133. Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev: 2012; 11 6-7 A479 A485
134. Pennell L. M., Galligan C. L., Fish E. N. Sex affects immunity. J Autoimmun: 2012; 38 2-3 J282 J291
135. Quintero O. L., Amador-Patarroyo M. J., Montoya-Ortiz G., Rojas-Villarraga A., Anaya J. M. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun: 2012; 38 2-3 J109 J119
136. Rogers M. A., Levine D. A., Blumberg N., Fisher G. G., Kabeto M., Langa K. M. Antigenic challenge in the etiology of autoimmune disease in women. J Autoimmun: 2012; 38 2-3 J97 J102
137. Selmi C., Brunetta E., Raimondo M. G., Meroni P. L. The X chromosome and the sex ratio of autoimmunity. Autoimmun Rev: 2012; 11 6-7 A531 A537
138. Shoenfeld Y., Tincani A., Gershwin M. E. Sex gender and autoimmunity. J Autoimmun: 2012; 38 2-3 J71 J73
139. Amur S., Parekh A., Mummaneni P. Sex differences and genomics in autoimmune diseases. J Autoimmun: 2012; 38 2-3 J254 J265
140. Mitchell M. M., Lleo A., Zammataro L., et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics: 2011; 6 1 95 102
141. Lleo A., Oertelt-Prigione S., Bianchi I., et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun: 2013; 41 87 91
142. Podda M., Selmi C., Lleo A., Moroni L., Invernizzi P. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun: 2013; 46 81 87
143. Padgett K. A., Lan R. Y., Leung P. C., et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun: 2009; 32 3-4 246 253
144. Qin B., Huang F., Liang Y., Yang Z., Zhong R. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol: 2013; 28 3 543 550
145. Banales J. M., Sáez E., Uriz M., et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology: 2012; 56 2 687 697
146. Ninomiya M., Kondo Y., Funayama R., et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS ONE: 2013; 8 6 e66086
147. Qian C., Chen S. X., Ren C. L., Zhong R. Q., Deng A. M., Qin Q. [Abnormal expression of miR-let-7b in primary biliary cirrhosis and its clinical significance]. Zhonghua Gan Zang Bing Za Zhi: 2013; 21 7 533 536
148. Selmi C., Invernizzi P., Miozzo M., Podda M., Gershwin M. E. Primary biliary cirrhosis: does X mark the spot? Autoimmun Rev: 2004; 3 7-8 493 499
149. Bouman A., Heineman M. J., Faas M. M. Sex hormones and the immune response in humans. Hum Reprod Update: 2005; 11 4 411 423
150. Invernizzi P., Miozzo M., Battezzati P. M., et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet: 2004; 363 9408 533 535
151. Borchers A. T., Naguwa S. M., Keen C. L., Gershwin M. E. The implications of autoimmunity and pregnancy. J Autoimmun: 2010; 34 03 J287 J299
152. Bogdanos D., Pusl T., Rust C., Vergani D., Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol: 2008; 49 3 466 473
153. Selmi C., Lleo A., Pasini S., Zuin M., Gershwin M. E. Innate immunity and primary biliary cirrhosis. Curr Mol Med: 2009; 9 1 45 51
154. Kikuchi K., Lian Z. X., Yang G. X., et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology: 2005; 128 2 304 312
155. Medzhitov R., Janeway C. A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science: 2002; 296 5566 298 300
156. Mogensen T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev: 2009; 22 2 240 273 Table of Contents
157. Mao T. K., Lian Z. X., Selmi C., et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology: 2005; 42 4 802 808
158. Moritoki Y., Lian Z. X., Wulff H., et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology: 2007; 45 2 314 322
159. Shimoda S., Harada K., Niiro H., et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology: 2011; 53 4 1270 1281
160. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol: 2000; 18 767 811
161. Demetris A. J., Sever C., Kakizoe S., Oguma S., Starzl T. E., Jaffe R. S100 protein positive dendritic cells in primary biliary cirrhosis and other chronic inflammatory liver diseases. Relevance to pathogenesis? Am J Pathol: 1989; 134 4 741 747
162. Tanimoto K., Akbar S. M., Michitaka K., Onji M. Immunohistochemical localization of antigen presenting cells in liver from patients with primary biliary cirrhosis; highly restricted distribution of CD83-positive activated dendritic cells. Pathol Res Pract: 1999; 195 3 157 162
163. Akbar S. M., Yamamoto K., Miyakawa H., et al. Peripheral blood T-cell responses to pyruvate dehydrogenase complex in primary biliary cirrhosis: role of antigen-presenting dendritic cells. Eur J Clin Invest: 2001; 31 7 639 646
164. Kita H., Lian Z. X., Van de Water J., et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med: 2002; 195 1 113 123
165. Hiasa Y., Akbar S. M., Abe M., Michitaka K., Horiike N., Onji M. Dendritic cell subtypes in autoimmune liver diseases; decreased expression of HLA DR and CD123 on type 2 dendritic cells. Hepatol Res: 2002; 22 4 241 249
166. Harada K., Shimoda S., Ikeda H., et al. Significance of periductal Langerhans cells and biliary epithelial cell-derived macrophage inflammatory protein-3. α in the pathogenesis of primary biliary cirrhosis. Liver Int: 2011; 31 2 245 253
167. Vandenbark A. A., Meza-Romero R., Benedek G., et al. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. J Autoimmun: 2013; 40 96 110
168. Honda Y., Yamagiwa S., Matsuda Y., Takamura M., Ichida T., Aoyagi Y. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol: 2007; 47 3 404 411
169. Takii Y., Nakamura M., Ito M., et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest: 2005; 85 7 908 920
170. Jin J. O., Han X., Yu Q. Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun: 2013; 40 28 44
171. Samavedam U. K., Kalies K., Scheller J., et al. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun: 2013; 40 74 85
172. Selmi C., Meroni P. L., Gershwin M. E. Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis. J Autoimmun: 2012; 39 1-2 34 42
173. Van den Oord J. J., Sciot R., Desmet V. J. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol: 1986; 3 3 310 317
174. Ayres R. C., Neuberger J. M., Shaw J., Joplin R., Adams D. H. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines. Gut: 1993; 34 9 1245 1249
175. Leon M. P., Bassendine M. F., Gibbs P., Thick M., Kirby J. A. Immunogenicity of biliary epithelium: study of the adhesive interaction with lymphocytes. Gastroenterology: 1997; 112 3 968 977
176. Tsuneyama K., Van de Water J., Leung P. S., et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology: 1995; 21 4 1031 1037
177. Ballardini G., Mirakian R., Bianchi F. B., Pisi E., Doniach D., Bottazzo G. F. Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet: 1984; 2 8410 1009 1013
178. Cha S., Leung P. S., Gershwin M. E., Fletcher M. P., Ansari A. A., Coppel R. L. Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proc Natl Acad Sci U S A: 1993; 90 6 2527 2531
179. Borchers A. T., Shimoda S., Bowlus C., Keen C. L., Gershwin M. E. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol: 2009; 31 3 309 322
180. Sakisaka S., Gondo K., Yoshitake M., et al. Functional differences between hepatocytes and biliary epithelial cells in handling polymeric immunoglobulin A2 in humans, rats, and guinea pigs. Hepatology: 1996; 24 2 398 406
181. Fukushima N., Nalbandian G., Van De Water J., et al. Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC. Hepatology: 2002; 36 6 1383 1392
182. Johansson S., Berg L., Hall H., Höglund P. NK cells: elusive players in autoimmunity. Trends Immunol: 2005; 26 11 613 618
183. Panasiuk A., Prokopowicz D., Zak J. Peripheral blood T, B lymphocytes and NK cells in primary biliary cirrhosis. Rocz Akad Med Bialymst: 2001; 46 231 239
184. Chuang Y. H., Lian Z. X., Tsuneyama K., et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun: 2006; 26 4 232 240
185. Shimoda S., Tsuneyama K., Kikuchi K., et al. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol: 2012; 168 3 279 284
186. Hudspeth K., Pontarini E., Tentorio P., et al. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun: 2013; 46 55 65
187. Kita H., Naidenko O. V., Kronenberg M., et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology: 2002; 123 4 1031 1043
188. Chuang Y. H., Lian Z. X., Yang G. X., et al. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology: 2008; 47 2 571 580
189. Wu S. J., Yang Y. H., Tsuneyama K., et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology: 2011; 53 3 915 925
190. Harada K., Van de Water J., Leung P. S., et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology: 1997; 25 4 791 796
191. Nagano T., Yamamoto K., Matsumoto S., et al. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol: 1999; 19 6 422 427
192. Lan R. Y., Salunga T. L., Tsuneyama K., et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun: 2009; 32 1 43 51
193. Trivedi P. J., Adams D. H. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun: 2013; 46 97 111
194. Fenoglio D., Bernuzzi F., Battaglia F., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev: 2012; 12 2 300 304
195. Lan R. Y., Cheng C., Lian Z. X., et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology: 2006; 43 4 729 737
196. Zhang W., Sharma R., Ju S. T., et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology: 2009; 49 2 545 552
197. Mayer C. T., Tian L., Hesse C., et al. Anti-CD4 treatment inhibits autoimmunity in scurfy mice through the attenuation of co-stimulatory signals. J Autoimmun: 2014; 50 23 32
198. Bernuzzi F., Fenoglio D., Battaglia F., et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun: 2010; 35 3 176 180
199. Oertelt-Prigione S., Mao T. K., Selmi C., et al. Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. Autoimmunity: 2008; 41 1 92 99
200. Selmi C., Podda M., Gershwin M. E. Old and rising stars in the lymphoid liver. Semin Immunopathol: 2009; 31 3 279 282
201. Shimoda S., Van de Water J., Ansari A., et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest: 1998; 102 10 1831 1840
202. Shimoda S., Harada K., Niiro H., et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology: 2008; 47 3 958 965
203. Shimoda S., Ishikawa F., Kamihira T., et al. Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology: 2006; 131 2 606 618
204. Shimoda S., Miyakawa H., Nakamura M., et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun: 2008; 31 2 110 115
205. Shimoda S., Nakamura M., Ishibashi H., Hayashida K., Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med: 1995; 181 5 1835 1845
206. Shimoda S., Nakamura M., Ishibashi H., et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology: 2003; 124 7 1915 1925
207. Shimoda S., Nakamura M., Shigematsu H., et al. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology: 2000; 31 6 1212 1216
208. Kita H., Matsumura S., He X. S., et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest: 2002; 109 9 1231 1240
209. Chabot S., Fakhfakh A., Béland K., et al. Mouse liver-specific CD8(+) T-cells encounter their cognate antigen and acquire capacity to destroy target hepatocytes. J Autoimmun: 2013; 42 19 28
210. Tanaka A., Nezu S., Uegaki S., et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci: 2007; 1107 259 270
211. Kim W. R., Poterucha J. J., Jorgensen R. A., et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology: 1997; 26 1 22 26
212. Invernizzi P., Crosignani A., Battezzati P. M., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology: 1997; 25 5 1090 1095
213. Cambridge G., Perry H. C., Nogueira L., et al. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun: 2014; 50 67 76
214. Moritoki Y., Lian Z. X., Ohsugi Y., Ueno Y., Gershwin M. E. B cells and autoimmune liver diseases. Autoimmun Rev: 2006; 5 7 449 457
215. Takahashi T., Miura T., Nakamura J., et al. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology: 2012; 55 3 846 855
216. Moritoki Y., Lian Z. X., Lindor K., et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology: 2009; 50 6 1893 1903
217. Tsuda M., Moritoki Y., Lian Z. X., et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology: 2012; 55 2 512 521
218. Dhirapong A., Lleo A., Yang G. X., et al. B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology: 2011; 53 2 527 535
219. Angulo P., Jorgensen R. A., Keach J. C., Dickson E. R., Smith C., Lindor K. D. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology: 2000; 31 2 318 323
220. Kaplan M. M., Bonder A., Ruthazer R., Bonis P. A. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci: 2010; 55 11 3207 3217
221. Munoz S. J. Cyclosporine in primary biliary cirrhosis. N Engl J Med: 1990; 323 19 1352
222. Gong Y., Christensen E., Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev: 2007; 3 CD006000
223. Wolfraim L. A. Treating autoimmune diseases through restoration of antigen-specific immune tolerance. Arch Immunol Ther Exp (Warsz): 2006; 54 1 1 13
224. Yin Y. F., Zhang X. B cell depletion in treating primary biliary cirrhosis: pros and cons. World J Gastroenterol: 2012; 18 30 3938 3940
225. Kawata K., Tsuda M., Yang G. X., et al. Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis. PLoS ONE: 2013; 8 9 e74225
226. Cingoz O. Ustekinumab. MAbs: 2009; 1 3 216 221
227. Kavanaugh A., Ritchlin C., Rahman P., et al. PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis: 2014; 73 6 1000 1006
228. Antonelli A., Ferrari S. M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev: 2014; 13 3 272 280
229. Chuang Y. H., Lian Z. X., Cheng C. M., et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun: 2005; 25 2 126 132
230. Dhirapong A., Yang G. X., Nadler S., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology: 2013; 57 2 708 715
231. Romo-Tena J., Gómez-Martín D., Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev: 2013; 12 12 1171 1176
232. Walker L. S. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun: 2013; 45 49 57
233. Figueroa F. E., Carrión F., Villanueva S., Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res: 2012; 45 3 269 277
234. Wang D., Zhang H., Liang J., et al. Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI:C-induced primary biliary cirrhosis mouse model. Clin Exp Med: 2011; 11 1 25 32
235. Wang L., Li J., Liu H., et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol: 2013; 28 01 85 92
236. Van Brussel I., Lee W. P., Rombouts M., et al. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality? Autoimmun Rev: 2014; 13 2 138 150
237. Weiner H. L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today: 1997; 18 7 335 343
238. Suzuki A., Van de Water J., Gershwin M. E., Jorgensen R., Angulo P., Lindor K. Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. Dev Immunol: 2002; 9 2 55 61
239. Goudy K. S., Annoni A., Naldini L., Roncarolo M. G. Manipulating immune tolerance with micro-RNA regulated gene therapy. Front Microbiol: 2011; 2 221
240. Pauley K. M., Cha S. RNAi therapeutics in autoimmune disease. Pharmaceuticals (Basel): 2013; 6 3 287 294
241. Ando Y., Yang G. X., Kenny T. P., et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun: 2013; 41 111 119
242. Singh R. P., Massachi I., Manickavel S., et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev: 2013; 12 12 1160 1165
243. Albani S., Koffeman E. C., Prakken B. Induction of immune tolerance in the treatment of rheumatoid arthritis. Nat Rev Rheumatol: 2011; 7 5 272 281
244. Imam M. H., Talwalkar J. A., Lindor K. D. Clinical management of autoimmune biliary diseases. J Autoimmun: 2013; 46 88 96
245. Bogdanos D. P., Baum H., Sharma U. C., et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol: 2002; 36 1 14 21
246. Kaplan M. M. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol: 2004; 99 11 2147 2149
247. Goo M. J., Ki M. R., Lee H. R., et al. Primary biliary cirrhosis, similar to that in human beings, in a male C57BL/6 mouse infected with Helicobacter pylori. Eur J Gastroenterol Hepatol: 2008; 20 10 1045 1048
248. Bogdanos D. P., Baum H., Gunsar F., et al. Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand J Gastroenterol: 2004; 39 10 981 987
249. Bogdanos D. P., Baum H., Okamoto M., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology: 2005; 42 2 458 465
250. Berg C. P., Kannan T. R., Klein R., et al. Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int: 2009; 29 6 797 809
251. Bogdanos D. P., Pares A., Baum H., et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun: 2004; 22 4 353 362
252. Bogdanos D. P., Koutsoumpas A., Baum H., Vergani D. Borrelia burgdorferi: a new self-mimicking trigger in primary biliary cirrhosis. Dig Liver Dis: 2006; 38 10 781 782, author reply 782-783
253. Zhao J., Zhao S., Zhou G., et al. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol: 2011; 46 4 485 494
254. Nakamura M., Ishibashi H., Matsui M., et al. Peripheral B lymphocyte repertoire to mitochondrial antigen in primary biliary cirrhosis-positive correlation between the disease activity and the frequency of circulating B lymphocytes specific for pyruvate dehydrogenase complex. Autoimmunity: 1995; 21 4 253 262
255. Silveira M. G., Lindor K. D. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother: 2014; 15 3 365 372